ZUBERITAMAB

DB19443InvestigationalProtein Based Therapies

Zuberitamab is under investigation in clinical trial NCT06642909 (A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy).

Mechanism: Pharmacologically active on B-lymphocyte antigen CD20
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human cd20 antigen) (human-mus musculus monoclonal hs006 .gamma.1-chain), disulfide with human-mus musculus monoclonal hs006 .kappa.-chain, dimer · Rhcacd20ma
Code names: HS-006

Resolves to

Compound

UNIIP1DFX74SQ8CAS2251143-19-6

Targets

P11836MS4A1

What you can answer from here — as of September 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with ZUBERITAMAB, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account